

1008 Rec'd PCT/PTO 10 APR 2001  
09/807172

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
REQUEST FOR FILING NATIONAL PHASE OF  
PCT APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495

To: Hon. Commissioner of Patents  
Washington, D.C. 20231



00909

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)

Atty Dkt: P 279470 /T 3077 (V)  
M# /Client Ref.

From: Pillsbury Winthrop LLP, IP Group:

Date: April 10, 2001

This is a **REQUEST** for **FILING** a PCT/USA National Phase Application based on:

- |  |  |  |
|--|--|--|
| 1. International Application<br><u>PCT/EP99/08323</u><br><u>1</u> country code | 2. International Filing Date<br><u>22</u> <u>October</u> <u>1999</u><br>Day MONTH Year | 3. Earliest Priority Date Claimed<br><u>27</u> <u>October</u> <u>1998</u><br>Day MONTH Year<br>(use item 2 if no earlier priority) |
|--|--|--|
4. Measured from the earliest priority date in item 3, this PCT/USA National Phase Application Request is being filed within:

(a) ☐ 20 months from above item 3 date (b) ☒ 30 months from above item 3 date

(c) Therefore, the due date (unextendable) is April 27, 2001

5. Title of Invention ANTIGEN-BINDING PROTEINS

6. Inventor(s) FRENKEN, Leo G. J. et al

Applicant herewith submits the following under 35 U.S.C. 371 to effect filing:

7. ☒ Please immediately start national examination procedures (35 U.S.C. 371 (f)).
8. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (file if in English but, if in foreign language, file only if not transmitted to PTO by the International Bureau) including:
- a. ☐ Request;
- b. ☐ Abstract;
- c.        pgs. Spec. and Claims;
- d.        sheet(s) Drawing which are ☐ informal ☐ formal of size ☐ A4 ☐ 11"
9. ☒ A copy of the International Application has been transmitted by the International Bureau.
10. A translation of the International Application into English (35 U.S.C. 371(c)(2))
- a. ☒ is transmitted herewith including: (1) ☒ Request; (2) ☒ Abstract;
- (3) 27 pgs. Spec. and Claims;
- (4) 7 sheet(s) Drawing which are:
- ☐ informal ☒ formal of size ☒ A4 ☐ 11"
- b. ☐ is not required, as the application was filed in English.
- c. ☐ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
- d. ☐ Translation verification attached (not required now).

JC08 Rec'd PCT/PTO 10 APR 2001

11. ☒ Please see the attached Preliminary Amendment
12. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., before 18th month from first priority date above in item 3, are transmitted herewith (file only if in English) including:
13. ☒ PCT Article 19 claim amendments (if any) have been transmitted by the International Bureau
14. ☐ Translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., of claim amendments made before 18th month, is attached (required by 20th month from the date in item 3 if box 4(a) above is X'd, or 30th month if box 4(b) is X'd, or else amendments will be considered canceled).
15. **A declaration of the inventor** (35 U.S.C. 371(c)(4))
- a. ☐ is submitted herewith ☐ Original ☐ Facsimile/Copy
- b. ☒ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
16. **An International Search Report (ISR):**
- a. Was prepared by ☒ European Patent Office ☐ Japanese Patent Office ☐ Other
- b. ☒ has been transmitted by the international Bureau to PTO.
- c. ☒ copy herewith (3 pg(s).) ☒ plus Annex of family members (1 pg(s).).
17. **International Preliminary Examination Report (IPER):**
- a. ☒ has been transmitted (if this letter is filed after 28 months from date in item 3) in English by the International Bureau with Annexes (if any) in original language.
- b. ☒ copy herewith in English.
- c.1 ☐ IPER Annex(es) in original language ("Annexes" are amendments made to claims/spec/drawings during Examination) including attached amended:
- c.2 ☐ Specification/claim pages # \_\_\_\_\_ claims # \_\_\_\_\_  
Dwg Sheets # \_\_\_\_\_
- d. ☐ Translation of Annex(es) to IPER (required by 30<sup>th</sup> month due date, or else annexed amendments will be considered canceled).
18. **Information Disclosure Statement** including:
- a. ☒ Attached Form PTO-1449 listing documents
- b. ☐ Attached copies of documents listed on Form PTO-1449
- c. ☒ A concise explanation of relevance of ISR references is given in the ISR.
19. ☐ **Assignment** document and Cover Sheet for recording are attached. Please mail the recorded assignment document back to the person whose signature, name and address appear at the end of this letter.
20. ☐ Copy of Power to IA agent.
21. ☐ **Drawings** (complete only if 8d or 10a(4) not completed): \_\_\_\_\_ sheet(s) per set: ☐ 1 set informal;  
☐ Formal of size ☐ A4 ☐ 11"
22. Small Entity Status ☒ is **Not** claimed ☐ is claimed (pre-filing confirmation required)
- 22(a) \_\_\_\_\_ (No.) Small Entity Statement(s) enclosed (since 9/8/00 Small Entity Statements(s) not essential to make claim)
23. **Priority** is hereby claimed under 35 U.S.C. 119/365 based on the priority claim and the certified copy, both filed in the International Application during the international stage based on the filing in (country) EUROPE of:
- |     | Application No. | Filing Date      |     | Application No. | Filing Date    |
|-----|-----------------|------------------|-----|-----------------|----------------|
| (1) | PCT/EP98/06991  | October 27, 1998 | (2) | 99303118.6      | April 22, 1999 |
| (3) |                 |                  | (4) |                 |                |
| (5) |                 |                  | (6) |                 |                |
- a. ☒ See Form PCT/IB/304 sent to US/DO with copy of priority documents. If copy has not been received, please proceed promptly to obtain same from the IB.
- b. ☐ Copy of Form PCT/IB/304 attached.

09/807172

Page 3 of 4

RE: USA National Phase Filing of PCT/EP99/08323

24. Attached: 14 pages of Sequence Listing

JC08 Rec'd PCT/PTO 10 APR 2001

25 Per Item 17.c2, **cancel original** pages #\_\_\_\_\_, claims #\_\_\_\_\_, Drawing Sheets #**26. Calculation of the U.S. National Fee (35 U.S.C. 371 (c)(1)) and other fees is as follows:**Based on amended claim(s) per above item(s) ☐ 12, ☐ 14, ☐ 17, ☐ 25 (hilit)

Total Effective Claims	minus 20 =	x \$18/\$9 =	\$0	966/967
Independent Claims	minus 3 =	x \$80/\$40 =	\$0	964/965
If any proper (ignore improper) Multiple Dependent claim is present,		add \$270/\$135	+0	968/969

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)): →→ **BASIC FEE REQUIRED, NOW** →→→→A. If country code letters in item 1 are **not** "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

See item 16 re:

- |  |                  |      |         |
|--|------------------|------|---------|
| 1. Search Report was <u>not</u> prepared by EPO or JPO ----- | add \$1000/\$500 |      | 960/961 |
| 2. Search Report was prepared by EPO or JPO -----            | add \$860/\$430  | +860 | 970/971 |

SKIP B, C, D AND E UNLESS country code letters in item 1 are "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

- |   |                 |    |         |
|---|-----------------|----|---------|
| (X) → <input type="checkbox"/> B. If <u>USPTO</u> did not issue <u>both</u> International Search Report (ISR) <u>and</u> (if box 4(b) above is X'd) the International Examination Report (IPER), -----                | add \$970/\$485 | +0 | 960/961 |
| (only) (one) → <input type="checkbox"/> C. If <u>USPTO</u> issued ISR but not IPER (or box 4(a) above is X'd), -----  | add \$710/\$355 | +0 | 958/959 |
| (of) (these) (4) → <input type="checkbox"/> D. If <u>USPTO</u> issued IPER but IPER Sec. V boxes <u>not all</u> 3 YES, -----  | add \$690/\$345 | +0 | 956/957 |
| → <input type="checkbox"/> E. If international preliminary examination fee was paid to <u>USPTO</u> and Rules 492(a)(4) and 496(b) <u>satisfied</u> (IPER Sec. V <u>all</u> 3 boxes YES for <u>all</u> claims), ----- | add \$100/\$50  | +0 | 962/963 |

27. **SUBTOTAL =** \$860

28. If Assignment box 19 above is X'd, add Assignment Recording fee of ----\$40 +0 (581)

29. Attached is a check to cover the ----- **TOTAL FEES** \$860

Our Deposit Account No. 03-3975

Our Order No. 60113 279470

C#

M#



00909

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 and 492 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed

**Pillsbury Winthrop LLP**  
**Intellectual Property Group**

By Atty: Paul N. Kokulis

Reg. No. 16773

Sig:

Fax: (202) 822-0944  
 Tel: (202) 861-3503

Atty/Sec: PNK/mhn

**NOTE:** File in duplicate with 2 postcard receipts (PAT-103) & attachments.

PTO/PCT Rec'd 03 JUL 2002

PATENT  
ATTORNEY DOCKET NO. 56159-5041

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Leo G. J. FRENKEN *et al.*** )  
Application No.: **09/807,172** ) Group Art Unit: **Not Assigned**  
Filed: **April 10, 2001** ) Examiner: **Not Assigned**  
For: **Antigen-Binding Proteins** )

**BOX SEQUENCE**

Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT ACCOMPANYING SEQUENCE LISTING**

The undersigned hereby states upon information and belief that the Sequence Listing submitted concurrently herewith does not include matter which goes beyond the content of the application as filed and that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,  
**MORGAN, LEWIS & BOCKIUS LLP**

Dated: July 3, 2002

By: Rachel B. Kapust

Rachel B. Kapust

**Customer No. 09629**  
**MORGAN, LEWIS & BOCKIUS LLP**  
1111 Pennsylvania Ave., NW  
Washington, DC 20004  
Tel: 202-739-3000; Fax: 202-739-3001

JC08 Rec'd PCT/PTO 10 APR 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION OF

Inventor(s): FRENKEN, Leo G. J. et al

Filed: Herewith

Title: ANTIGEN-BINDING PROTEINS

April 10, 2001

**PRELIMINARY AMENDMENT**

Hon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

Please amend this application as follows:

**IN THE SPECIFICATION:**

At the top of the first page, just under the title, insert


☒ --This application is the National Phase of International Application  
PCT/EP99/08323 filed October 22, 1999 which designated the U.S.  
and that International Application

☒ was ☐ was not published under PCT Article 21(2) in English.--

Respectfully submitted,

PILLSBURY WINTHROP LLP  
Intellectual Property Group

By:

  
Attorney: Paul N. Kokulis  
Reg. No: 16773  
Tel. No.: (202) 861-3503  
Fax No.: (202) 822-0944

Atty\Sec. PNK/mhn  
1100 New York Avenue, NW  
Ninth Floor  
Washington, DC 20005-3918  
(202) 861-3000

09/807172

JC08 Rec'd PCT/PTO 10 APR 2001

7/PRTS

WO 00/24884

PCT/EP99/08323

ANTIGEN-BINDING PROTEINS

FIELD OF THE INVENTION

5 The present invention relates to the preparation of multivalent and multispecific binding proteins. In particular, the invention relates to the preparation of antigen binding proteins comprising a plurality of binding units linked in series by means of intervening polypeptide linker groups, the amino acid  
10 sequence of which linker groups confer restricted conformational flexibility.

BACKGROUND OF THE INVENTION

15 There is considerable interest in the preparation of multivalent and/or multispecific antigen binding proteins. Antigen binding proteins which are multivalent (that is, comprise more than one antigen binding site), more especially those which are also multispecific (where the antigen binding sites have differing  
20 antigen specificities) have found particular application in the fields of diagnosis or therapy, for example, where the construction of binding proteins having binding activity against both target site and diagnostic or therapeutic agent allows for targeted delivery of the diagnostic or therapeutic agent to the  
25 intended site of action. Other uses for which multivalent and multispecific binding proteins have been proposed include assays, such as immunoassays and agglutination assays, and purification processes.

30 Those multivalent, multispecific antigen binding proteins which have been described in the literature to date rely, in general, on the association of antibody light and heavy chain variable domains for the formation of the antigen binding site.

35 Thus, constructs comprising two or more polypeptide chains are described in WO 94/09131 (Scotgen Limited) and WO 97/14719

(Unilever) and WO 97/38102 (Unilever); multivalent molecules comprising two or more single chain Fv molecules linked together are described in WO 93/11161 (Enzon Inc.) and WO 94/13806 (Dow Chemical Co.).

5

WO 94/04678 (Casterman et al) describes immunoglobulins capable of exhibiting the functional properties of classical, four chain, immunoglobulins but which comprise two heavy polypeptide chains only and are naturally devoid of light polypeptide chains. Fragments corresponding to isolated VH domains or to VH dimers linked by the hinge disulphide are also disclosed. These immunoglobulins, which may be isolated from Camelids, do not rely on the association of heavy and light chain variable domains for the formation of the antigen-binding site; instead, the heavy chain variable domain (hereinafter VHH) alone forms the complete antigen binding site, constituting a single domain binding site.

In their later patent application, WO 96/34103, Casterman et al disclose multivalent, multispecific constructs comprising VHH fragments combined with a linker sequence. Suitable linker sequences disclosed and exemplified are derived from sequences corresponding to the hinge domain of an immunoglobulin devoid of light chains.

25

In the Applicant's co-pending patent publication number WO 99/23221, published after the priority date of the present application, there are disclosed multivalent, multispecific antigen-binding proteins comprising a polypeptide comprising in series two or more single domain binding units which are preferably variable domains of a heavy chain derived from an immunoglobulin naturally devoid of light chains. The individual single domain binding units may suitably be linked by means of peptide linkers, preferably flexible peptide linkers, which allow the variable domains to flex in relation to each other

with the aim of ensuring that they can bind to multiple antigenic determinants simultaneously.

There remains a continuing need for the development of improved methods for producing multivalent and/or multispecific binding proteins, especially antigen binding proteins. In particular, there is commercial interest in producing molecules which not only have improved binding activity but which also can be produced economically on a large scale.

10

# SUMMARY OF THE INVENTION

In a first aspect, the invention provides the use of a polypeptide group, the amino acid sequence of which group confers restricted conformational flexibility, as a linking group to link binding units in a multivalent binding protein.

The invention also provides a multivalent binding protein comprising a plurality of binding units linked by means of intervening polypeptide linker groups, the amino acid sequence of which linker group confers restricted conformational flexibility.

The invention further provides a nucleotide sequence encoding a multivalent antigen binding protein according to the invention and cloning and expression vectors comprising such nucleotide sequences. Also provided are host cells transformed with vectors comprising such nucleotide sequences.

As used herein, a 'multivalent binding protein' is a protein which has more than one binding units which allow for specific binding with a molecule partner in a binding pair. Included within this are bivalent, trivalent and so on. Examples of suitable binding units include antigen binding domains of antibodies, binding domains of receptors such as hormone receptors, lectins, enzymes, and cell adhesion molecules. A



'multivalent antigen binding protein' is a protein which has more than one antigen binding unit.

An 'antigen binding unit' is any structure which exhibits  
5 antigen-binding activity. This may be an antibody or an immunologically active fragment thereof. An 'antibody' refers to an immunoglobulin which may be derived from natural sources or synthetically produced. Unless indicated otherwise, 'antibody' and 'immunoglobulin' are used synonymously throughout  
10 this specification.

An antibody fragment is a portion of a whole antibody which retains the ability to exhibit antigen-binding activity. The antigen binding site may be formed through association of  
15 antibody light and heavy chain variable domains or may comprise individual antibody variable domains, constituting a single domain binding site.

Suitable fragments include Fab (comprising an antibody light  
20 chain associated with the  $V_H$  and  $C_{H1}$  domains of an antibody heavy chain), Fv (comprising the variable domains of antibody heavy and light chains associated with each other) and scFv (comprising an antibody  $V_H$  domain linked to a  $V_L$  domain by a flexible peptide linker) fragments. Where the antigen binding  
25 site comprises a single variable domain, this may be a heavy chain variable domain, most suitably a heavy chain variable domain derived from an immunoglobulin naturally devoid of light chains.

30 'Restricted conformational flexibility' relates to restriction of movement of the antigen binding units about the backbone of the intervening polypeptide linker group.

The present invention may be more fully understood with  
35 reference to the following description, when read together with the accompanying drawings. For convenience, an antigen binding

protein comprising two single binding units is hereinafter referred to as a 'bi-head'.

BRIEF DESCRIPTION OF THE DRAWINGS

5

Figure 1 shows a nucleotide sequence of the PstI-BstEII insert of plasmid pUR4640, encoding the heavy chain variable domain of an anti-RR6 antibody (denoted R9) from a llama.

10

Figure 2 shows the nucleotide sequence of the PstI-BstEII insert of plasmid pUR4601, encoding the heavy chain variable domain of an anti-hCG antibody (denoted H14) from a llama.

15

Figure 3 shows a map of plasmid pUR4619.

20

Figure 4 shows the nucleotide sequence within plasmid pUR4619 which encodes an anti-hCG-anti-RR6 bispecific biheaded antigen-binding protein (denoted HI4-R9), missing the first 4 and last 3 amino acids.

25

Figure 5 shows the A405 signals of an ELISA to determine bispecificity of various HI4-R9 biheads.

30

Figure 6 shows the scores achieved in a rapid assay technology (RAT) format assay following the detection of 1 IU/ml hCG (human chorionic gonadotrophin protein) with various anti-hCG-anti-RR6 bihead antigen binding proteins derived from a llama wherein the anti-hCG and anti-RR6 fragments are linked as follows (see Example 1.5):

Number	Linker	
1	no linker (directly attached)	
2	G-T-S-G-S	(SEQ. ID NO. 1)
3	S-S-S-A-S-A-S-S-A	(SEQ. ID NO. 2)
4	G-S-P-G-S-P-G	(SEQ. ID NO. 3)
5	A-T-T-T-G-S-S-P-G-P-T	(SEQ. ID NO. 4)
6	A-N-H-S-G-N-A-S	(SEQ. ID NO. 5)

Figure 7 shows a comparison of the sensitivity of detection of hCG in a RAT assay using various biheads (see Example 1.5).

5

#### DETAILED DESCRIPTION OF THE INVENTION

The invention is based on the unexpected finding that by using a polypeptide linking group conferring restricted conformational flexibility to link together antigen binding units, multivalent antigen binding proteins having advantageous binding affinity, as demonstrated by their increased sensitivity of diagnosis and detection, are obtained. Furthermore, constructs according to the invention may conveniently be produced at high yields economically and efficiently on a scale appropriate for industrial use.

As is apparent from the discussion of the background to the invention above, to the extent that multivalent antigen binding constructs comprising separate binding units linked together have been described at all in the literature, the linking means has been provided by flexible peptide groups. Flexibility of conformation in the linker group has been considered desirable in order to allow the multivalent construct to assume the correct orientation to allow simultaneous binding of multiple antigens.

Surprisingly, the present inventors have found that by restricting the conformational flexibility of the linking polypeptide group, multivalent antigen binding constructs having improved binding affinity may be obtained. This is entirely  
5 contrary to the teaching in the art that the linking group should desirably be flexible.

The invention is applicable to the preparation of multivalent antigen binding constructs comprising antigen binding units  
10 where the antigen binding site is formed through association of antibody light and heavy chain variable domains. Preferably, however, the constructs prepared according to the invention comprise a plurality of single domain binding units, more particularly a plurality of heavy chain variable domains derived  
15 from an immunoglobulin naturally devoid of light chains such as may be obtained from lymphoid cells, especially peripheral blood lymphocytes, bone marrow cells or spleen cells derived from Camelids as described in WO 94/04678 (Casterman et al) discussed above. An advantage of using single domain binding units which  
20 are heavy chain variable domains derived from Camelids is that they can readily and conveniently be produced economically on a large scale, for example, using a transformed lower eukaryotic host, as described in WO 94/25591 (Unilever), described above.

25 It will be appreciated that heavy chain variable domains derived from other immunoglobulins modified ('camelised') to enable them to function as single binding domains in the same way as the heavy chain variable domains derived from Camelids may also suitably be used according to the invention.

30

Bivalent forms, that is having two antigen binding sites, of the multivalent antigen binding proteins prepared according to the invention are preferred but it will be appreciated that higher multivalent forms, which are also encompassed in the present  
35 invention, may find application under suitable circumstances, for example where more than two antigens are required to bind,

for example in processes for scavenging molecules from solution or processes where close proximity of molecules form the basis of an assay.

5 Structural features which may suitably be incorporated into the linking polypeptide group in order to achieve the effect of restricting conformational flexibility according to the purposes of the invention would readily suggest themselves to those skilled in the art.

10

Accordingly, in one embodiment, the linker group preferably comprises one or more proline residues.

Without wishing to be bound by theory, it is generally thought  
15 that the presence of a proline residue in a peptide sequence encourages the amino acid backbone of the peptide to adopt a beta-turn structural configuration, with the peptide backbone changing direction about the proline residue. Linker groups comprising other sequence features which promote the formation  
20 of a beta-turn configuration in the peptide backbone, such as peptide linkers containing valine residues or constrained residues such as 8-bicyclic and 5,9-bicyclic tripeptide units (see, for example, Johannesson et al, J. Med. Chem., 42, 601-608 (1999), may also suitably find application in the present  
25 invention.

In another embodiment, peptide linker groups derived from naturally occurring proteins such as cell wall proteins (CWP), in particular, CWP1, or cellobishydrolases (CBH), such as CBH1P,  
30 which serve to restrict conformational flexibility or linker groups showing at least 50% homology thereto as determined by the ALIGN program of Dayhoff et al (1983), Methods Enzymol., 91, 524-545, may also suitably be used according to the invention.

35 Peptide linker groups which encode a glycosylation binding site and/or are resistant to proteolytic attack may also suitably be

employed. Here, the presence of a carbohydrate attached to the amino acid residues has the effect of restricting the flexibility of the peptide backbone.

- 5 Conveniently, the polypeptide linking group according to the invention comprises from 4 to 30 amino acid residues, preferably from 5 to 15 amino acid residues.

Preferred polypeptide linking groups according to the invention  
10 comprise an amino acid sequence selected from:

S-S-S-A-S-A-S-S-A, (SEQ. ID NO. 2)

G-S-P-G-S-P-G, (SEQ. ID NO. 3)

A-T-T-T-G-S-S-P-G-P-T (SEQ. ID NO. 4)

15

It will be appreciated that although the invention has been described primarily by reference to antigen binding proteins, it is equally applicable to proteins comprising other binding units as described above. References to antigen binding proteins will  
20 accordingly be understood to refer also to such other proteins unless the context dictates otherwise.

Multivalent antigen binding proteins according to the invention may be prepared by transforming a host by incorporating a gene  
25 encoding the polypeptide as set forth above and expressing said gene in said host.

Suitably the host or hosts may be selected from prokaryotic bacteria, such as Gram-negative bacteria, for example *E. coli*,  
30 and Gram-positive bacteria, for example *B. subtilis* or lactic acid bacteria, lower eukaryotes such as yeasts, for example belonging to the genera *Saccharomyces*, *Kluyveromyces*, *Hansenula* or *Pichia*, or moulds such as those belonging to the genera *Aspergillus* or *Trichoderma*.

35

Preferred hosts for use in connection with the present invention are the lower eukaryotic moulds and yeasts.

Techniques for synthesising genes, incorporating them into hosts  
5 and expressing genes in hosts are well known in the art and the skilled person would readily be able to put the invention into effect using common general knowledge.

Methods for producing antibody fragments or functionalised  
10 fragments thereof derived from the heavy chain immunoglobulin of *Camelidae* using a transformed lower eukaryotic host are described, for example in patent application WO 94/25591 and such techniques may suitably be applied to prepare constructs according to the present invention.

15 Proteins according to the invention may be recovered and purified using conventional techniques such as affinity chromatography, ion exchange chromatography or gel filtration chromatography.

20 The activity of the multivalent binding proteins according to the invention may conveniently be measured by standard techniques known in the art such as enzyme-linked immunoadsorbant assay (ELISA), radioimmune assay (RIA) or by  
25 using biosensors.

The following examples are produced by way of illustration only. Techniques used for the manipulation and analysis of nucleic acid materials were performed as described in Sambrook et al,  
30 Molecular Cloning, Cold Spring Harbor Press, New York, 2nd Ed., (1989) unless otherwise indicated.

Restriction sites are underlined.

HC-V denotes heavy chain variable domain.

35

EXAMPLES

Example 1 Self Assembling Llama Bi-heads Containing Linker Peptides on Latex to Assay hCG

5

1.1 Construction of Llama Bi-heads with Various Linkers

a) Induction of humeral immune responses in llama

10 Male llamas were immunised with a water in oil emulsion (1:9 V/V, antigen in water: Specol (Bokhout et al, Vet. Immunol. Immunopath., 2:, 491-500 (1981)) subcutaneously and intramuscularly. Per immunisation site 0.75-1.5 ml water in oil emulsion was inoculated containing 100:g antigen. The antigens  
15 used were: hCG (Sigma), azo-dye RR6 (ICI) which was coupled to BSA via its reactive triazine group. Immunisations were performed according to the following time table: The second immunisation was performed three weeks after the first. The third was performed two weeks after the second immunisation.  
20 The immune response was followed by antigen specific ELISAs.

The anti-RR-6 response was measured by using Nunc Covalink plates, which where coated with the azo-dye. After incubation with (diluted) serum samples, the bound llama antibodies were  
25 detected via a incubation with poly-clonal rabbit-anti-llama antiserum (obtained via immunising rabbits with llama immunoglobulins which were purified via ProtA and ProtG columns; ID-DLO), followed by an incubation with swine-anti-rabbit immunoglobulins (Dako) conjugated with alkaline phosphatase.  
30 Finally the alkaline phosphatase enzyme-activity was determined after incubation with p-nitro-phenyl phosphate and the optical density was measured at 405nm. The anti-hCG response, was measured in essentially the same way using Nunc maxi-sorb plates coated with hCG.

35



b) Cloning, expressing and screening of llama HC-V fragments

i) Isolation of gene fragments encoding llama HC-V domains

5 From an immunised llama a blood sample of about 200ml was taken and an enriched lymphocyte population was obtained via Ficoll (Pharmacia) discontinuous gradient centrifugation. From these cells, total RNA was isolated by acid guanidium thiocyanate extraction (e.g. via the method described by Chomczynski and  
10 Sacchi, Analytical Biochemistry, 162: 156-159 (1987). After first strand cDNA synthesis (e.g. with the Amersham first strand cDNA kit), DNA fragments encoding HC-V fragments and part of the long or short hinge region were amplified by PCR using specific primers:

15

*Pst*I

V<sub>H</sub> - 2B 5'-AGGTSMARCTGCAGSAGTCWGG-3' (SEQ. ID NO. 6)

S = C and G, M = A and C, R = A and G, W = A and T,

20

*Hind*III

Lam-07 5'-AACAGTTAAGCTTCCGCTTGCGGCCGCGGAGCTGGGGTCTTCGCTGTGGTGCG-3'  
(short hinge) (SEQ. ID NO. 7)

25

*Hind*III

Lam-08 5'-AACAGTTAAGCTTCCGCTTGCGGCCGCTGGTTGTGGTTTTGGTGTCTTGGGTT-3'  
(long hinge) (SEQ. ID NO. 8)

Upon digestion of the PCR fragments with *Pst*I (coinciding with  
30 codon 4 and 5 of the HC-V domain, encoding the amino acids L-Q) and *Bst*EII (located at the 3'-end of the HC-V gene fragments, coinciding with the amino acid sequence Q-V-T), the DNA fragments with a length between 300 and 400bp (encoding the HC-V domain, but lacking the first three and the last three codons)  
35 were purified via gel electrophoresis and isolation from the agarose gel.

ii) Construction of *Saccharomyces cerevisiae* expression plasmids encoding llama HC-V domains

Plasmids pUR4547 and pUR4548 are *Saccharomyces cerevisiae* episomal expression plasmids, derived from pSY1 (Harmsen et al., Gene, 125: 115-123, (1993)). From pSY1 the *Pst*I site, located in front of the GAL7 promoter was removed after partial digestion with *Pst*I, incubation with Klenow fragment and subsequent blunt end ligation. After transformation the desired plasmid could be selected on the basis of restriction pattern analysis. Subsequently, the *Bst*EII site in the Leu2 selection marker was removed by replacing the about 410bp *Afl*III/*Pfl*MI fragment with a corresponding fragment in which the *Bst*EII site was removed via a three step PCR mutagenesis, using the primers:

PCR-A:

BOLI 1 5'-GGGAATTCCAATAGGTGGTTAGCAATCG (SEQ. ID NO. 9)

BOLI 4 5'-GACCAACGTGGTCGCCTGGCAAAACG (SEQ. ID NO. 10)

PCR-B:

BOLI 3 5'-CGTTTTGCCAGGCGACCACGTTGGTC (SEQ. ID NO. 11)

BOLI 2 5'-CCCCAAGCTTACATGGTCCTTAAGTTGGCGT (SEQ. ID NO. 12)

PCR-A was performed with primers BOLI 1 and BOLI 4 and resulted in an about 130bp fragment with the *Pfl*MI restriction site at the 3'-end and the inactivated *Bst*EII site at the 5'-end. PCR-B was performed with primers BOLI 2 and BOLI 3 and resulted in an about 290bp fragment with the *Afl*III site at the 5'-end. The third PCR was with the fragments obtained from reaction A and B, together with the primers BOLI 1 and BOLI 2.

Finally, the about 1.8kb *SacI*-*HindIII* fragment was replaced with synthetic fragments, having sequences as presented below, resulting the plasmids pUR4547 and pUR4548, respectively.

5 - *SacI*/*HindIII* fragment of pUR4547

```

SacI                                     (SEQ. ID NO. 13-16)
GAGCTCATCACACAAACAAACAAACAAATGATGCTTTTGCAAGCCTTCCCTT
1  -----+-----+-----+-----+-----+----- 54
10 CTCGAGTAGTGTGTTTGTGTTTGTGTTTGTGTTTACTACGAAAACGTTTCGGAAGGGAA
      M M L L Q A F L F
      |→      SUC2 ss

                                     PstI
15  TTCCTTTTGGCTGGTTTTGTCAGCCAAAATATCTGCGCAGGTGCAGCTGCAGG
55-----+-----+-----+-----+-----+----- 105
AAGGAAAACCGACCAAACGTCGGTTTTATAGACGCGTCCACGTCGACGTCC
  L L A G F A A K I S A Q V Q L Q E
      |→

20                                     BstEII                                     HindIII
AGTCATAATGAGGGACCCAGGTCACCGTCTCCTCATAATGACTTAAGCTT
106-----+-----+-----+-----+-----+----- 155
TCAGTATTACTCCCTGGGTCCAGTGGCAGAGGAGTATTACTGAATTCGAA
25  E S * * G T Q V T V S S * *
      HC-V cassette      ←|

```

and

30 - *SacI*/*HindIII* fragment of pUR4548

```

SacI                                     (SEQ. ID NO. 17-20)
GAGCTCATCACACAAACAAACAAACAAATGATGCTTTTGCAAGCCTTCCCTT
1  -----+-----+-----+-----+-----+----- 54
35 CTCGAGTAGTGTGTTTGTGTTTGTGTTTGTGTTTACTACGAAAACGTTTCGGAAGGAAA
      M M L L Q A F L F
      |→      SUC2 ss

                                     PstI
40  TCCTTTTGGCTGGTTTTGTCAGCCAAAATATCTGCGCAGGTGCAGCTGCAGG
55-----+-----+-----+-----+-----+----- 105
AGGAAAACCGACCAAACGTCGGTTTTATAGACGCGTCCACGTCGACGTCC
  L L A G F A A K I S A Q V Q L Q E
      |→

45

```

*BstEII*

```

AGTCATAATGAGGGACCCAGGTCACCGTCTCCTCAGAACAAAACTCATC
106-----+-----+-----+-----+-----+----- 155
TCAGTATTACTCCCTGGGTCCAGTGGCAGAGGAGTCTTGTGTTTTGAGTAG
5      S * * G T Q V T V S S E Q K L I
      HC-V cassette                ←|→ myc tail

```

*HindIII*

```

TCAGAAGAGGATCTGAATTAATGACTTAAGCTT
10 156-----+-----+-----+-----+----- 188
AGTCTTCTCCTAGACTTAATTACTGAATTCGAA
      S E E D L N * *
      ←|

```

15 Both plasmids contain the GAL7 promoter and PGK terminator sequences as well as the invertase (SUC2) signal sequence. In both plasmids the DNA sequence encoding the SUC2 signal sequence is followed by the first 5 codons, (encoding Q-V-Q-L-Q) of the HC-V domain (including the *BstEII* site), a stuffer sequence, the

20 last six codons (encoding Q-V-T-V-S-S) of the HC-V domain. In pUR4547, this is followed by two stop codons, an *AflIII* and *HindIII* site. In pUR4548, this sequence is followed by eleven codons encoding the myc-tag, two stop codons, an *AflIII* and *HindIII* site.

25 Plasmids pUR4547 and pUR4548 were deposited under the Budapest Treaty at the Centraal Bureau voor Schimmelcultures, Baarn on 18th August 1997 with deposition numbers: CBS 100012 and CBS 100013, respectively. In accordance with Rule 28(4) EPC, or a

30 similar arrangement from a state not being a contracting state of the EPC, it is hereby requested that a sample of such deposit, when requested, will be submitted to an expert only.

35 Upon digesting pUR4548 with *PstI* and *BstEII*, the about 6.4kb vector fragment was isolated and ligated with the *PstI*-*BstEII* fragments of about 350bp obtained as described above. After transformation of *S. cerevisiae*, via electroporation, transformants were selected from minimal medium agar plates

(comprising 0.7% yeast nitrogen base, 2% glucose and 2% agar, supplemented with the essential amino acids and bases).

iii) Screening for antigen specific HC-V domains

5 For the production of llama HC-V fragments with myc-tail, individual transformants were grown overnight in selective minimal medium (comprising 0.7% yeast nitrogen base, 2% glucose, supplemented with the essential amino acids and bases) and  
10 subsequently diluted ten times in YPGal medium (comprising 1% yeast extract, 2% bacto pepton and 5% galactose). After 24 and 48 hours of growth, the culture supernatant of the colonies was analysed by ELISA for the presence of HC-V fragments which specifically bind to the antigens hCG, RR6 in essential the same  
15 way as described above. In this case, however, the presence of specifically bound HC-V fragments was detected by incubation with monoclonal anti-myc antibodies, followed by incubation with poly-clonal rabbit-anti-mouse conjugate with alkaline phosphatase. In this way a number of anti-hCG and anti-RR6 HC-V  
20 fragments were isolated, which are:

anti-RR6:

R9 pUR4640 (see Figure 1) (SEQ. ID NO. 21-22)

25

anti-hCG (alpha unit):

H14 pUR4601 (see Figure 2) (SEQ. ID NO. 23-24)

30 c) Production of llama HC-V biheads by *S. cerevisiae*

i) Construction of episomal expression plasmids encoding anti-hCG/anti-RR6 bispecific biheads

In the anti-hCG HC-V fragment H14 (anti-alpha-subunit), the *Pst*I site was removed and a *Xho*I site was introduced via PCR, using the primers:

5 MPG158WB

*Xho*I  
5'-GAATTAAGCGGCCGCCAGGTGAAACTGCTCGAGTCWGGGGGA-3' (SEQ. ID NO. 25)

and

10

MPG159WB

*Bst*EII  
3'-CCCTGGGTCCAGTGGCAGAGGAGTGGCAGAGGAGTCTTGTTT-5' (SEQ. ID NO. 26)

15 In this way the sequence:

*Pst*I  
CAG GTC CAG CTG CAG GAG TCT GGG (SEQ. ID NO. 27)  
Q V Q L Q E S G

20

became

*Xho*I  
CAG GTG AAA CTG CTC GAG TCW GGG (SEQ. ID NO. 28)  
25 Q V K L L E S G

Upon digesting the PCR fragments with *Xho*I and *Bst*EII, the about 330bp fragments were purified via agarose gel electrophoresis and isolation from the gel. The fragments were cloned into pUR4421 (see Example 1 in WO 94/25591) which was digested with the same enzymes, resulting in pJS2 (H14). Subsequently, the about 420bp *Eag*I -*Hind*III fragment of pJS2 was isolated and ligated in the about 6.6kb *Eag*I-*Hind*III vector fragment of the pSY1 plasmid of which the *Pst*I and *Bst*EII sites were removed as described above. The resulting plasmid pJS7, was digested with *Bst*EII and *Hind*III, after which the purified vector fragment was religated in the presence of a synthetic linker having the following sequence:

30

35

(SEQ. ID NO. 29-31)

```

      BstEII                      PstI                      HindIII
      <-                          MPG 160 WB (49)              ->
5  GGTCAACCGTCTCCTCACAGGTGCAGCTGCAGGAGTCACTGTAATGACTTAAGCTT
   -----+-----+-----+-----+-----+----- 55
      CCAGTGGCAGAGGAGTGTCCACGTCGACGTCCTCAGTGACATTACTGAATTCGAA
      <-                          MPG 161 WB (48)              ->
      V  T  V  S  S  Q  V  Q  L  Q  E  S  L  *  *  L  K  L

```

10

resulting in plasmid pJS9. Finally, the plasmid was digested with *Pst*I and *Hind*III, after which the purified vector fragments of about 7.0kb were ligated with the *Pst*I -*Hind*III fragments of about 350bp of pUR4638 and pUR4640, encoding an anti-RR6 HC-V fragment denoted R9 followed by the myc-tail. The resulting

15 *S. cerevisiae* episomal expression plasmid pUR4619 encodes a anti-hCG-anti-RR6 bispecific bihead preceded by the SUC2 signal sequence and followed by the myc-tail.

20 pUR4619: SUC2 - H14 - R9 - myc

(see Figures 3-4/SEQ. ID NO. 32-33)

Upon digesting these plasmids with *Xho*I and partially with *Bst*EII, *Xho*I-*Bst*EII fragments of about 0.7kb can be isolated and

25 subsequently cloned into the vector fragment of pUR4547 (digested with the same enzymes). In this way biheads can be obtained without the myc tail.

It will be appreciated that expression vectors can be

30 constructed in which different promoter systems, e.g. the constitutive GAPDH promoter or different signal sequences, e.g. the mating factor prepro sequence are used.

ii) Production of the HC-V biheads

35

After introducing the expression plasmid pUR4619 into *S. cerevisiae* via electroporation, transformants were selected

from minimal medium agar plates as described in part b(ii) above. For the production of biheads, the transformants were grown overnight in selective minimal medium and subsequently diluted ten times in YPGal medium. After 24 and 48 hours of growth, samples were taken for Western blot analysis. For the immuno detection of the produced biheads via Western blot analysis, monoclonal anti-myc antibodies were used, followed by incubation with poly-clonal rabbit-anti-mouse conjugate with alkaline phosphatase.

10

- d) Anti-hCG/anti-RR6 bispecific biheads containing a linker peptide
- i) Construction of *S. cerevisiae* episomal expression plasmids encoding anti-hCG/anti-RR6 bispecific biheads containing a linker peptide

Between the H14 and the R9 encoding DNA fragments synthetic linkers were introduced encoding different linker peptides. To this end the about 50 bp long *Bst*EII-*Hind*III fragment of pJS7 (see Example 1 c(i) above) was replaced by an about 50 bp long *Bst*EII-*Hind*III fragment having the following sequence:

MVaJA

25      *Bst*EII      *Xba*I      *Dra*III      *Pst*I      *Hind*III  
5' GTCACCGTCTCTAGATGGCCACCAGGTGCAGCTGCAGGAGTCAACTTA 3'

(SEQ. ID NO. 34)

MVbJA

30      3'      GCAGAGATCTACCGGTGGTCCACGTCGAGCTCCTCAGTTGAATTCCA 5'

(SEQ. ID NO. 35)

This resulted in pSJ7a. In this plasmid the about 20 bp *Pst*I-*Hind*III fragment was replaced with the about 370 bp *Pst*I-*Hind*III fragment encoding the anti-RR6 HC-V fragment R9 and/or with the myc-tail of pUR4640 (see Example 1 c(i)) and resulting in pSJ7b.



WO 00/24884

20

PCT/EP99/08323

Upon digesting plasmid pSJ7b with *Xba*I and *Dra*III the about 7 kb vector fragment was ligated with five synthetic oligo nucleotide linker fragments presented below:

5

MV01JA 5' CTAGTGGTACTTCCGGTCCCAG 3' (SEQ. ID NO. 36)

MV02JA 3' ACCATGAAGGCCAAGG 5' (SEQ. ID NO. 37)

10

S G T S G S Q

MV03JA 5' CTAGTTCTTCATCTGCTTCTGCCTCTTCAGCCCAG 3' (SEQ. ID NO. 38)

15

MV04JA 3' AAGAAGTAGACGAAGACGGAGAAGTCGG 5' (SEQ ID NO. 39)

S S S S A S A S S A Q

MV05JA 5' CTAGTGGTTCTCCAGGTTACCAGGTCAG 3' (SEQ. ID NO. 40)

20

MV06JA 3' ACCAAGAGGTCCAAGTGGTCCA 5' (SEQ. ID NO. 41)

S G S P G S P G Q

25

MV07JA 5' CTAGTGCTACTACAAGTGGTTCTTCACCAGGTCCAAGTCAG 3' (SEQ. ID NO. 42)

MV08JA 3' ACGATGATGTTGACCAAGAAGTGGTCCAGGTTGA 5' (SEQ. ID NO. 43)

30

S A T T T G S S P G P T Q

MV09JA 5' CTAGTGCTAATCATTCTGTAATGCTTCTCAG 3'

(SEQ. ID NO. 44)

MV10JA 3' ACGATTAGTAAGACCATTACGAAGA 5' (SEQ. ID NO. 45)

5

S A N H S G N A S Q

The oligonucleotide linker fragments encode the last amino acid of the N-terminal HC-V fragment (S) and the first amino acid of the C-terminal HC-V fragment, intersected by the connecting linker peptide. This resulted in plasmids pUR5330 to 5334, respectively.

After transformation of *S. cerevisiae* with these plasmids, the production levels of the biheads were determined via Western blot analysis and a anti-hCG ELISA using anti-myc mAb for detection of the bound bihead (see Example 1 b(iii)). Production levels are presented in Table 2 below:

20 Table 2

Plasmid	Linker	Production level (mg/l)
pUR4619	None	11
pUR5330	S-G-T-S-G-S-Q	36
pUR5331	S-S-S-S-A-S-A-S-S-A-Q	49
pUR5332	S-G-S-P-G-S-P-G-Q	33
pUR5333	S-A-T-T-T-G-S-S-P-G-P-T-Q	56
pUR5334	S-A-N-H-S-G-N-A-S-Q	51

The production levels of the biheads in which the two HC-V domains are separated by a linker peptide (consisting of between 5 and 11 amino acids) were found to be 3 to 5 times higher as found for the bihead in which the two HC-V fragments are connected without a peptide linker.

Finally, the bispecificity of the biheads was demonstrated as follows:

5    PINs coated with hCG were incubated with (diluted) medium samples. Subsequently, the PINs were incubated with a RR6-alkaline phosphatase conjugate, in which the azo-dye RR6 was coupled to the alkaline phosphatase via its reactive triazine group. Finally, the alkaline phosphatase enzyme activity was  
10    determined after incubation of the PINs with p-nitro-phenyl phosphate and the optical density was measured at 405nm (see Figure 5).

15    1.2    Purification of Llama Bi-heads with Various Linkers from *S. cerevisiae* Culture Media

A 5 ml column of recombinant Protein A Fast Flow Sepharose (Amersham Pharmacia Biotech) was equilibrated by washing with 10 column volumes of wash buffer (10 mM potassium phosphate, pH 6),  
20    at a flow rate of 2 ml/min. The bi-head fermentation broth was loaded at 2 ml/min in an upwards direction. After loading, the column was washed with wash buffer until the OD<sub>280</sub> reached the baseline. Elution was carried out with a linear gradient of 0 - 40 mM citric acid pH 2.5 in the reverse direction, collecting 4  
25    ml fractions into tubes containing 400 µl of a neutralising agent (1M Tris.Cl, pH 8.5) in order to minimise the effects of the acid. Peak fractions were checked for purity by running on a 12% SDS-PAGE Ready Gel (Bio-Rad) under standard denaturing conditions. Staining was with GelCode Blue (Pierce & Warriner).  
30    The fractions were concentrated using Macrosep centrifugal concentrators (3 kDa molecular weight cut-off, Pall Filtron Corp.) then buffer exchanged into 10mM potassium phosphate, pH 6 using PD-10 columns (Amersham Pharmacia Biotech). The final purity of the sample was determined by carrying out a UV scan  
35    from 400 - 220 nm and using the value at 280 nm to determine an

accurate concentration. The samples were then aliquoted into vials, frozen, freeze dried and stored until required.

### 1.3 Preparation of a Reactive Red 6-Bovine Serum Albumin Conjugate

A solution of Reactive Red 6 (RR6) was made up at 10 mg/ml in phosphate buffered saline (PBS). A solution of bovine serum albumin (BSA) was made up at 10 mg/ml in PBS. 200 µl of the RR6 solution was added to 800 µl of the BSA solution and the resulting solution was mixed in an end over end rotary mixer for 2 hours at room temperature. RR6 that had conugated to BSA was separated from free RR6 by addition of the reaction mixture (1 ml) to a PD10 column (Pharmacia) previously washed with 10 ml of PBS containing 0.1% sodium azide (PBSA). The column was then eluted by addition of PBSA (5 ml) and 1 ml aliquots were collected. The RR6-BSA conjugate eluted in fractions 4 and 5. These were pooled and the concentration of protein was determined using a BCA protein test and the concentration adjusted to 2 mg/ml with PBSA.

### 1.4 Adsorption of Latex with Reactive Red 6-Bovine Serum Albumin Conjugate

Duke blue latex was adsorbed with the RR6-BSA conjugate as follows:

To 950 µl of 10 mM borate buffer, 0.01 % merthiolate, pH 8.5 (buffer B) a 50 µl aliquot of Duke blue latex (10 % solids) was added and mixed by inverting. The diluted latex was centrifuged at 8000 g for 10 minutes at room temperature, the supernatant removed and the pellet vortexed briefly. The pellet was resuspended in 900 µl of buffer B and to this 100 µl of the previously prepared RR6-BSA conjugate was added. The latex solution was sonicated for 10 s using a sonic probe. The

solution containing the latex was mixed for 2 h at room temperature and then centrifuged (8000 g, 10 min at room temperature). The latex pellet was washed by resuspending in 1 ml of buffer B and centrifuged once more (8000 g, 10 min at room temperature). The pellet was then resuspended in 1 ml buffer B ready for use.

1.5 Analysis of Llama Bi-head Self Assembling on Reactive Red 6-Bovine Serum Albumin Adsorbed Latex

10

The llama bi-heads were tested by self assembling onto RR6-BSA adsorbed latex and detection of hCG in a rapid assay technology (RAT) format. This was performed by mixing the llama bi-head (5 µl of a 0.1 mg/ml solution) with RR6-BSA adsorbed latex (5 µl of 0.1 % solids) in 10 µl of PBSA, to which hCG (5 µl of various concentrations) was added. The resulting solution was added to the bottom of a nitrocellulose strip (6 mm wide x 30 mm long) on which a monoclonal antibody recognising hCG had been adsorbed by plotting in a line (2.5 mg/ml) mid way up the strip. The latex-bi-head-hCG solution was allowed to flow up the nitrocellulose strip by capillary action and the strip was then washed by applying PBSA (25 µl) to the bottom of the strip. The amount of latex, captured at the plotted antibody line on the nitrocellulose strip, was quantified by measuring the absorbance through the strip.

Figure 6 shows that the llama bi-heads with linkers 3, 4 and 5 gave the highest response in RAT assays. These linkers are structurally more ordered than the comparative examples, flexible linkers 2 and 6 and result in more hCG and more latex captured in the assay. The more ordered linkers promote the correct orientation of the binding domains to achieve more optimal binding than when no linker is used. Linker 3 is derived from CWP1 and Linker 5 from CBH1P.

35

WO 00/24884

25

PCT/EP99/08323

Synthetic linkers with some order (linker 4 containing 2 proline residues) can offer increased sensitivity in assays than those with little order (linker 2). Figure 7 shows that the bi-head with linker 4 can detect lower amounts (50 mIU/ml) of hCG than  
 5 the bi-head with linker 2 and, hence, give a more sensitive assay for hCG.

CLAIMS

1. Use of a polypeptide group, the amino acid sequence of which group confers restricted conformational flexibility,  
5 as a linking group to link binding units in a multivalent binding protein.
2. Use according to claim 1 wherein the polypeptide linking group comprises from 4 to 30 amino acid residues.
- 10 3. Use according to claim 1 or 2 wherein the linking group comprises one or more proline residues.
4. Use according to claim 1 or 2 wherein the linking group  
15 comprises an amino acid sequence selected from:  
  
S-S-S-A-S-A-S-S-A,  
G-S-P-G-S-P-G, or  
A-T-T-T-G-S-S-P-G-P-T.
- 20 5. A multivalent binding protein comprising a plurality of binding units linked by means of intervening polypeptide linker groups, the amino acid sequence of which linker group confers restricted conformational flexibility.
- 25 6. A protein according to claim 5 wherein the binding units comprise heavy chain variable domains derived from an immunoglobulin naturally devoid of light chains.
- 30 7. A protein according to claim 5 or claim 6 wherein the antigen binding units comprise heavy chain variable domains derived from a Camelid immunoglobulin.
8. A protein according to any one of claims 5 to 7 comprising  
35 a bivalent antigen binding protein.

WO 00/24884

27

PCT/EP99/08323

9. A protein according to any one of claims 5 to 8 wherein the linker group comprises from 4 to 30 amino acid residues.
10. A protein according to any one of claims 5 to 9 wherein the linker group comprises one or more proline residues.
11. A protein according to any one of claims 5 to 9 wherein the linker group comprises an amino acid sequence selected from:  
S-S-S-A-S-A-S-S-A,  
G-S-P-G-S-P-G, or  
A-T-T-T-G-S-S-P-G-P-T.
12. Nucleotide sequences encoding for a multivalent binding protein of any one of claims 5 to 11.
13. An expression vector comprising a nucleotide sequence according to claim 12.
14. A host cell transformed with a vector according to claim 13.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/11, C07K 19/00, 16/46, C12N 1/19, 15/81</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/24884</b>
			(43) International Publication Date: 4 May 2000 (04.05.00)
(21) International Application Number: PCT/EP99/08323		<p>Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). VAN DER VAART, Jan, Marcel [NL/NL]; Unilever Research Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL).</p> <p>(74) Agent: EVANS, Jacqueline, Gail, Victoria; Unilever PLC, Patent Dept., Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>	
(22) International Filing Date: 22 October 1999 (22.10.99)			
(30) Priority Data: PCT/EP98/06991 27 October 1998 (27.10.98) EP 99303118.6 22 April 1999 (22.04.99) EP			
(71) Applicant (for AE AU BB CA CY GB GD GH GM IE IL KE LC LK LS MN MW NZ SD SG SL SZ TT TZ UG ZA ZW only): UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB).			
(71) Applicant (for all designated States except AE AU BB CA CY GB GD GH GM IE IL IN KE LC LK LS MN MW NZ SD SG SL SZ TT TZ UG US ZA ZW): UNILEVER NV [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).			
(71) Applicant (for IN only): HINDUSTAN LEVER LIMITED [IN/IN]; Hindustan Lever House, 165/166 Backbay Reclamation, Maharashtra, Mumbai 400 020 (IN).			
(72) Inventors; and (75) Inventors/Applicants (for US only): FRENKEN, Leon, Gerardus, Joseph [NL/GB]; (GB). HOWELL, Steven [GB/GB]; Unilever Research Colworth, Colworth House,			
(54) Title: ANTIGEN-BINDING PROTEINS			
(57) Abstract			
Use of a polypeptide linker group, the amino acid sequence of which group confers restricted conformational flexibility, as a linking group to link binding units, preferably antigen binding units comprising heavy chain variable domains derived from an immunoglobulin naturally devoid of light chains, in a multivalent binding protein.			

**Fig. 1.**

PstI  
 1 CAGGTGCAGCTGCAGGAGTCAGGGGAGGCTTGCTGCAGCTGGGAGTCTCTGAAACTCTCCTGTGCAGCCTCTCGAAACACACCTTCAGT  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 GTCCACGTCGACGTCCTCAGTCCCCCTCCGAACACGTCGACCCCTCAGAGACTTTGAGAGGACACGTCGGAGACCTTTGTGGAAGTCA  
 Q V Q L Q E S G G G L V Q A G E S L K L S C A A S G N T F S  
 [-> CDR I  
 90  
  
 KpnI  
 91 GGCGGCTTCATGGGCTGATACGCCAGGCTCCAGGGAAGCAGCGCGAGTTGGTCGAACCAATTAATAGTAGAGGTATCACAAACTATGCA  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 CCGCGAAGTACCGACCATGGCGGTCCGAGGTCCTTCGTCGGGTCAACGAGCGTTGGTAATTATCATCTCCATAGTGTGTTGATACGT  
 G G F M G W Y R Q A P G K Q R E L V A T I N S R G I T N Y A  
 [-> . CDR II  
 <->  
 181 GACTTCGTGAAGGGCGGATTCACCATCTCCAGAGACAAATGCCAAGAAGACAGTGTATTGGAAATGAACAGCCTGGAACCTGGAAGACACG  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 CTGAAGCACTCCCGGCTAAGTGGTAGAGTCTCTGTTACGGTTCCTCTGTGCATAAACCTTTACTTGTGCGGACCTTGGACATCTGTGC  
 D F V K G R F T I S R D N A K K T V Y L E M N S L E P E D T  
 <->  
 BstEII  
 271 GGCGTTTATTACTGTTACACTCACTACTTCAGATCCTACTGGGGTCAGGGGACCCAGGTCACCGTCTCCTCA  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 CGGCAATAATGACAATGTGAGTGATGAAGTCTAGGATGACCCAGTCCCTGGTCCACTGGCAGAGGAGT  
 A V Y Y C Y T H Y F R S Y W G Q G T Q V T V S S  
 [-> CDR III <->  
 342

Fig.2.

PstI  
 CAGGTGCAGCTGCAGGAGTCAGGGGAGGATTGGTCCAGGCGGGGGCTCTCTGAGACTCTCTGTCAGCCCTCTGGACGCACCGGCAGT  
 1-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 90  
 GTCCACGTCGACCTCCTCAGTCCCCCTCCTAACCGTCCGCGCCCGAGAGACTCTGAGAGGACACGTCGGAGACCTCGGTGGCCCGTCA  
 Q V Q L Q E S G G L V Q A G G S L R L S C A A S G R T G S  
 ACGTATGACATGGGCTGGTTCGCGCCAGGCTCCAGGAGGAGCGTGAGTCTGTAGCAGCTATTAACTGGGATAGTGGCGGCACATACTAT  
 91-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 180  
 TGCACTACTGTACCGACCAAGCGGTCCGAGGTCCCTTCTCGCACTCAGACATCGTCGATPAATTGACCCCTATCACCAGCGGTGTATGATA  
 T Y D M G W F R Q A P G K E R E S V A A I N W D S A R T Y Y  
 1-> CDR I <-1  
 1-> CDR II  
 EagI  
 GCAAGTCCGTGAGGGCCGATTACCATCTCCAGAGACACGCCAAGAGACGGTGTATCTGCAATGAACAGCCTGAACCTGAGGAC  
 181-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 270  
 CGTTCGAGGCACCTCCCGGCTAAGTGGTAGAGGTCTCTGTTCGGTCTCTTCCACATAGACGTTTACTGTGCGGACTTGGACTCCTG  
 A S S V R G R F T I S R D N A K K T V Y L Q M N S L K P E D  
 <-1  
 BstEII  
 ACGGCCGTTTATACCTGTGGCGGGGGAAGGTGGTACTTGGGACTCTGTGGGCGGAGGACCCAGGTACCGTCTCCTCA  
 271-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 351  
 TGGCCGCAATATGGACACCGGCGCCCTTCCACCATGAACCTGAGGACCCCGTCCCTGGTCCAGTGGCAGAGGAGT  
 T A V Y T C G A G E G T W D S W G Q G T Q V T V S S  
 1-> CDR III <-1

Fig.3.




Fig.4.

XhoI  
 1 CTCGAGTCAGGGGAGGATGGTGCAGGGGGGGGCTCTCTGAGACTCTCCTGTGCAGCCTCTGGACGCCGCGCAGTACGTATGACATG 90  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 GAGCTCAGTCCCCCTCCTAACCAACGTCGCCGCCCGAGAGACTGTGAGAGGACACGTCGGAGACCTGCGTGGCCGCTCATGTCATCTGTAC  
 L E S G G G L V Q A G G S L R L S C A A S G R T G S T Y D M  
 1--> CDR I  
 91 GGCTGGTCCCGCAGGCTCCAGGAGGAGCGGTGAGTCTGTAGCAGCTATTAACTGGGATAGTGGCGCACATACTATGCAAGCTCCGTG 180  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 CCGACCAAGGCGGTCCGAGGTCCCTTCCTCGCACTCAGACATCGTCGATAATTGACCCCTATCACGGCGGTGTATGATACGTCGAGGCAC  
 G W, F R Q A P G K E R E S V A A I N W D S A R T Y Y A S S V  
 1--> CDR II  
 181 AGGGGCCGATTACCAATCTCCAGAGACAACGCCAAGAGACGGTGTATCTGCAATGAACAGCCTGAAACCTGAGGACACGCCCGTTTAT 270  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 TCCCCGGCTAAGTGGTAGAGGTCTCTGTGCGGTTCTTCTGCCACATAGACGTTTACTTGTGGACTTTTGGACTCCTGTGCGCGGCAATA  
 R G R F T I S R D N A K K T V Y L Q M N S L K P E D T A V Y  
 <-1  
 271 ACCTGTGGCGGGGAGGTGGTACTTGGGACTCCTGGGGCCAGGGACCCAGTCAACCGTCTCTCACAGTGCAGTGCAGGAGTCA 360  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 TGGACACCGGCGCCCTTCCACCATGACCCCTGAGGACCCCGGTCCTGGTCCAGTGGCAGAGGAGTGTCCACGTCGACGTCCTCAGT  
 T C G A G E G T W D S W G Q G T Q V T V S S Q V Q L Q E S  
 1--> CDR III <-1  
 360

Fig.4(Cont.)

WO 00/24884

PCT/EP99/08323

5/7


361  
GGGGAGGCTTGGTGCAGGCTGGGGAGTCTCTGAAACTCTCTGTGCAGCCTCTGGAACACCTTCAGTGGGGCTTCATGGGCTGGTAC  
KpnI  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
450  
CCCCCTCGAACCACCGTCCGACCCCTCAGAGACTTTGAGAGGACACGTCGGAGACCTTTGTGGAAGTCACCGCCGGAAGTACCCGACCATG  
G G G L V Q A G E S L K L S C A A S G N T F S G G F M G W Y  
1-> CDR I <-1

451  
CGCCAGGCTCCAGGGAAGCAGCGCGAGTTGGTCCCAACCAATTAATAGTAGAGGTATCACAACTATGCAGACTTCGTGAAGGGCCGATTC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
540  
GCGGTCCGAGGTCCCTTCGTGCGGCTCAACCAGCGTTGGTAATTATCATCTCCATAGTGTGTTGATACGCTCTGAAGCACTTCCCGGCTAAG  
R Q A P G K Q R E L V A T I N S R G I T N Y A D F V K G R F  
1-> CDR II <-1

541  
ACCATCTCCAGAGACAATGCCAAGAAGACAGTGTATTGGGAATGAACAGCCCTGGAACCTGAAGACACGGCCGTTATTACTGTTACACT  
EagI  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
630  
TGGTAGAGGTCTCTGTTACGGTTCTTCTGTACATAAACCTTTACTTGTGCGGACCTTGACTTCTGTGCGGCAATAATGACAATGTGA  
T I S R D N A K K T V Y L E M N S L E P E D T A V Y Y C Y T

631  
CACTACTCAGATCCTACTGGGGTCAGGGGACCCAGGTCACC  
BstEII  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
672  
GTGATGAAGTCTAGGATGACCCAGTCCCTCGGTCCAGTGG  
H Y F R S Y W G Q G T Q V T  
1-> CDR III <-1

Fig.5.



pUR4619	■	pUR5333	◇
pUR5330	◆	pUR5334	*
pUR5331	★	blanc	○
pUR5332	□		

Fig.6.





Fig.7.





# **COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**

(includes Reference to PCT International Applications)

Attorney's Docket No. ....

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## **ANTIGEN-BINDING PROTEINS**

the specification of which (check only one item below)

- ☐ is attached hereto
- ☐ was filed as United States application  
Serial No. ....  
on .....  
and was amended  
on (if applicable) .....
- ☒ was filed as PCT international application  
Number PCT/EP99/08323  
on 22 Oct 1999  
and was amended under PCT Article 19  
on (if applicable) .....

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

## **PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
P.C.T.	PCTEP9806991	27 Oct 1998	YES
EUROPE	99303118.6	22 April 1999	YES

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

## **PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:**

### **U.S. APPLICATIONS**

U.S.APPLICATION NUMBER	U.S.FILING DATE	STATUS
None		

# PCT APPLICATIONS DESIGNATING THE U.S.

PCT APPLICATION NO.

PCT FILING DATE

U.S. SERIAL NUMBERS  
ASSIGNED (if any)

STATUS

None

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (List name and registration number)

Name	Registration No.	Name	Registration No.
Paul N Kokuls	16773	Keven E Joyce	20508
W Warren Taltavull	25647	Lawrence Harbin	27644
Raymond F Lippitt	17519	Edward M Prince	22429
Watson T Scott	26581	Wallace G Walter	27843
G Lloyd Knight	17698	Donald B Deaver	23048
Peter W Gowdey	25872	Paul E White, Jr	32011
Carl G Love	18781	David W Brunkman	20817
Dale S Lazar	28872	Nancy J Linck	31920
Lawrence A Hymo	19057	George M Sirilla	18221
Glenn J Perry	28458	Edgar H Martin	20534
William T Bullinger	25503	Kendrew H Colton	30368
William K West, Jr.	22057	Donald J Bird	25323
Chris Comuntzis	31097		

Send correspondence to:

1100 New York Avenue, Northwest, Ninth Floor, East Tower, Washington, D.C. 20005, U.S.A.

Direct telephone calls to:

Name:

Telephone No.: 861-3000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

First Inventor: 1-00 Leo Gerardus Joseph FRENKEN

Residence (City, State or Province, Country): Vlaardingen, Netherlands

Country of Citizenship: Netherlands

Post Office Address: c/o Unilever Research Vlaardingen, Unilever Health Institute, P.O. Box 114, 3130 AC Vlaardingen, Netherlands

Signature (Sign full name as it appears above):

Dated:

Month (in full) March Day 29, 2001

Second Inventor: 2-00 Steven HOWELL

Residence (City, State or Province, Country): Bedford, GBX United Kingdom

Country of Citizenship: United Kingdom

Post Office Address: Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, MK44 1LQ, United Kingdom

Signature (Sign full name as it appears above):

Dated:

Month (in full) March Day 24<sup>th</sup>, 2001

Third Inventor: 3-00 Jan Marcel Van Der Vaart

Residence (City, State or Province, Country): Vlaardingen, Netherlands

Country of Citizenship: Netherlands

Post Office Address: c/o Unilever Research Vlaardingen, Olivier van Noortlaan 120, 3133 AT Vlaardingen, Netherlands

Signature (Sign full name as it appears above):

Dated:

Month (in full) March Day 29, 2001

WO 00/24884

1

PCT/EP99/08323

SEQUENCE LISTING

5 <110> UNILEVER PLC  
UNILEVER N.V.

<120> ANTIGEN BINDING PROTEINS

10 <130> T3077

<140>  
<141>

15 <160> 45

<170> PatentIn Ver. 2.1

20 <210> 1  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:LINKER

25 <400> 1  
Gly Thr Ser Gly Ser  
1 5

30 <210> 2  
<211> 9  
<212> PRT  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence:LINKER

40 <400> 2  
Ser Ser Ser Ala Ser Ala Ser Ser Ala  
1 5

45 <210> 3  
<211> 7  
<212> PRT  
<213> Artificial Sequence

50 <220>  
<223> Description of Artificial Sequence:LINKER

<400> 3  
Gly Ser Pro Gly Ser Pro Gly  
1 5

55 <210> 4  
<211> 11  
<212> PRT  
<213> Artificial Sequence

60 <220>  
<223> Description of Artificial Sequence:PRIMER

65 <400> 4

WO 00/24884

2

PCT/EP99/08323

Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro Thr  
1 5 10

5 <210> 5  
<211> 8  
<212> PRT  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence:PRIMER

<400> 5  
Ala Asn His Ser Gly Asn Ala Ser  
15 1 5

<210> 6  
<211> 22  
20 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PRIMER

25 <400> 6  
aggtsmarct gcagsagtcw gg 22

30 <210> 7  
<211> 53  
<212> DNA  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence:PRIMER

<400> 7  
40 aacagttaag cttccgcttg cggccgcgga gctggggtct tcgctgtggt gcg 53

<210> 8  
<211> 53  
<212> DNA  
45 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PRIMER

50 <400> 8  
aacagttaag cttccgcttg cggccgctgg ttgtgggttt ggtgtcttgg gtt 53

<210> 9  
55 <211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
60 <223> Description of Artificial Sequence:PRIMER

<400> 9  
gggaattcca ataggtggtt agcaatcg 28

65

WO 00/24884

3

PCT/EP99/08323

5 <210> 10  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence:PRIMER  
 <400> 10  
 10 gaccaacgtg gtcgcctggc aaaacg 26  
 <210> 11  
 <211> 26  
 15 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence:PRIMER  
 20 <400> 11  
 cgttttgccg ggcgaccacg ttggtc 26  
 25 <210> 12  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 30 <220>  
 <223> Description of Artificial Sequence:PRIMER  
 <400> 12  
 35 ccccaagctt acatggtctt aagtggcgt 30  
 <210> 13  
 <211> 155  
 <212> DNA  
 40 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence:PLASMID  
 CONSTRUCT  
 45 <220>  
 <221> CDS  
 <222> (3)..(110)  
 50 <220>  
 <221> CDS  
 <222> (117)..(140)  
 55 <220>  
 <221> CDS  
 <222> (147)..(155)  
 <400> 13  
 60 ga gct cat cac aca aac aaa caa aac aaa atg atg ctt ttg caa gcc 47  
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala  
 1 5 10 15  
 65 ttc ctt ttc ctt ttg gct ggt ttt gca gcc aaa ata tct gcg cag gtg 95  
 Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val  
 20 25 30

```

5      cag  ctg  gag  tca  taatga  ggg  acc  cag  gtc  acc  gtc  tcc  tca  taatga  146
      Gln  Leu  Gln  Glu  Ser          Gly  Thr  Gln  Val  Thr  Val  Ser  Ser
          35                      40
10     ctt  aag  ctt
      Leu  Lys  Leu
          45
15     <210> 14
      <211> 36
      <212> PRT
      <213> Artificial Sequence
20     <223> Description of Artificial Sequence:PLASMID
      CONSTRUCT

      <400> 14
      Ala  His  His  Thr  Asn  Lys  Gln  Asn  Lys  Met  Met  Leu  Leu  Gln  Ala  Phe
          1              5              10              15

      Leu  Phe  Leu  Leu  Ala  Gly  Phe  Ala  Ala  Lys  Ile  Ser  Ala  Gln  Val  Gln
          20              25              30

25     Leu  Gln  Glu  Ser
          35
          ;

30     <210> 15
      <211> 8
      <212> PRT
      <213> Artificial Sequence
      <223> Description of Artificial Sequence:PLASMID
35     CONSTRUCT

      <400> 15
      Gly  Thr  Gln  Val  Thr  Val  Ser  Ser
          1              5

40     <210> 16
      <211> 3
      <212> PRT
      <213> Artificial Sequence
45     <223> Description of Artificial Sequence:PLASMID
      CONSTRUCT

      <400> 16
      Leu  Lys  Leu
50     1

      <210> 17
      <211> 188
      <212> DNA
      <213> Artificial Sequence

      <220>
      <223> Description of Artificial Sequence:PLASMID
60     CONSTRUCT

      <220>
      <221> CDS
      <222> (3)..(110)
65

```

WO 00/24884

5

PCT/EP99/08323

<220>  
 <221> CDS  
 <222> (117) .. (173)

5 <220>  
 <221> CDS  
 <222> (180) .. (188)

<400> 17  
 10 ga gct cat cac aca aac aaa caa aac aaa atg atg ctt ttg caa gcc 47  
     Ala His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala  
         1                    5                    10                    15

15 ttc ctt ttc ctt ttg gct ggt ttt gca gcc aaa ata tct gcg cag gtg 95  
     Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val  
                     20                    25                    30

20 cag ctg cag gag tca taatga ggg acc cag gtc acc gtc tcc tca gaa 143  
     Gln Leu Gln Glu Ser Gly Thr Gln Val Thr Val Ser Ser Glu  
                     35                    40                    45

25 caa aaa ctc atc tca gaa gag gat ctg aat taatga ctt aag ctt 188  
     Gln Lys Leu Ile Ser Glu Glu Asp Leu Xaa Xaa Lys Leu  
                     50                    55

<210> 18  
 <211> 36  
 <212> PRT  
 30 <213> Artificial Sequence  
 <223> Description of Artificial Sequence: PLASMID  
     CONSTRUCT

<400> 18  
 35 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala Phe  
     1                    5                    10                    15

40 Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val Gln  
                     20                    25                    30

Leu Gln Glu Ser  
     35

45 <210> 19  
 <211> 19  
 <212> PRT  
 <213> Artificial Sequence  
 <223> Description of Artificial Sequence: PLASMID  
 50 CONSTRUCT

<400> 19  
 Gly Thr Gln Val Thr Val Ser Ser Glu Gln Lys Leu Ile Ser Glu Glu  
     1                    5                    10                    15

55 Asp Leu Xaa

60 <210> 20  
 <211> 3  
 <212> PRT  
 <213> Artificial Sequence  
 <223> Description of Artificial Sequence: PLASMID  
 65 CONSTRUCT

WO 00/24884

6

PCT/EP99/08323

```

<400> 20
Xaa Lys Leu
1

5
<210> 21
<211> 342
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Description of Artificial Sequence:PLASMID
CONSTRUCT

15
<220>
<221> CDS
<222> (1)..(342)

<400> 21
20 cag gtg cag ctg cag gag tca ggg gga ggc ttg gtg cag gct ggg gag 48
    Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu
    1 5 10 15

25 tct ctg aaa ctc tcc tgt gca gcc tct gga aac acc ttc agt ggc ggc 96
    Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly Gly
    20 25 30

30 ttc atg ggc tgg tac cgc cag gct cca ggg aag cag cgc gag ttg gtc 144
    Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
    35 40 45

35 gca acc att aat agt aga ggt atc aca aac tat gca gac ttc gtg aag 192
    Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val Lys
    50 55 60

40 ggc cga ttc acc atc tcc aga gac aat gcc aag aag aca gtg tat ttg 240
    Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu
    65 70 75

45 gaa atg aac agc ctg gaa cct gaa gac acg gcc gtt tat tac tgt tac 288
    Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr
    85 90 95

50 act cac tac ttc aga tcc tac tgg ggt cag ggg acc cag gtc acc gtc 336
    Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr Val
    100 105 110

    tcc tca 342
    Ser Ser

55
<210> 22
<211> 114
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:PLASMID
CONSTRUCT

60
<400> 22
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly Gly
20 25 30

65

```



WO 00/24884

7

PCT/EP99/08323

Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val  
35 40 45

Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val Lys  
5 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu  
65 70 75 80

10 Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr  
85 90 95

Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr Val  
100 105 110

15 Ser Ser

<210> 23  
20 <211> 351  
<212> DNA  
<213> Artificial Sequence

<220>  
25 <223> Description of Artificial Sequence: PLASMID  
CONSTRUCT

<220>  
30 <221> CDS  
<222> (1)..(351)

<400> 23  
cag gtg cag ctg cag gag tca ggg gga gga ttg gtg cag gcg ggg ggc 48  
Gln Val Gln Leu Gln Glu Ser Gly Gly Leu Val Gln Ala Gly Gly  
1 5 10 15

35 tct ctg aga ctc tcc tgt gca gcc tct gga cgc acc ggc agt acg tat 96  
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr  
20 25 30

40 gac atg ggc tgg ttc cgc cag gct cca ggg aag gag cgt gag tct gta 144  
Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val  
35 40 45

45 gca gct att aac tgg gat agt gcg cgc aca tac tat gca agc tcc gtg 192  
Ala Ala Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val  
50 55 60

50 agg ggc cga ttc acc atc tcc aga gac aac gcc aag aag acg gtg tat 240  
Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr  
65 70 75 80

55 ctg caa atg aac agc ctg aaa cct gag gac acg gcc gtt tat acc tgt 288  
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys  
85 90 95

ggc gcg ggg gaa ggt ggt act tgg gac tcc tgg ggc cag ggg acc cag 336  
Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln  
100 105 110

60 gtc acc gtc tcc tca 351  
Val Thr Val Ser Ser  
115

65

WO 00/24884

8

PCT/EP99/08323

<210> 24  
 <211> 117  
 <212> PRT  
 <213> Artificial Sequence  
 5 <223> Description of Artificial Sequence: PLASMID  
 CONSTRUCT  
  
 <400> 24  
 10 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr  
 20 25 30  
 15 Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val  
 35 40 45  
 Ala Ala Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val  
 50 55 60  
 20 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys  
 25 85 90 95  
 Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln  
 100 105 110  
 30 Val Thr Val Ser Ser  
 115  
  
 35 <210> 25  
 <211> 43  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 40 <223> Description of Artificial Sequence: PRIMER  
  
 <400> 25  
 gaattaagcg gccgcccagg tgaaactgct cgagtcwggg gga 43  
  
 45 <210> 26  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence  
  
 50 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <400> 26  
 55 ccctgggtcc agtggcagag gagtggcaga ggagtcttgt tt 42  
  
 60 <210> 27  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 65 <223> Description of Artificial Sequence: PRIMER

WO 00/24884

9

PCT/EP99/08323

<400> 27  
caggtccagc tgcaggagtc tggg 24

5 <210> 28  
<211> 24  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence:PRIMER

<400> 28  
caggtgaaac tgctcgagtc wggg 24

15

<210> 29  
<211> 55  
20 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:LINKER;DOUBLE  
25 STRANDED

<220>  
<221> CDS  
<222> (2)..(40)

30

<220>  
<221> CDS  
<222> (47)..(55)

35 <400> 29  
g gtc acc gtc tcc tca cag gtg cag ctg cag gag tca ctg taatga ctt 49  
Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Xaa Xaa  
1 5 10

40 aag ctt 55  
Lys Leu  
15

45 <210> 30  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
<223> Description of Artificial Sequence:LINKER;DOUBLE  
50 STRANDED

<400> 30  
Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Xaa  
1 5 10

55

<210> 31  
<211> 3  
<212> PRT  
60 <213> Artificial Sequence  
<223> Description of Artificial Sequence:LINKER;DOUBLE  
STRANDED

<400> 31  
65 Xaa Lys Leu

	1																					
5		<210> 32 <211> 672 <212> DNA <213> Artificial Sequence																				
10		<220> <223> Description of Artificial Sequence: PLASMID CONSTRUCT																				
15		<220> <221> CDS <222> (1)..(672)																				
20		<400> 32 ctc gag tca ggg gga gga ttg gtg cag gcg ggg ggc tct ctg aga ctc 48 Leu Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu 15																				
25		tcc tgt gca gcc tct gga cgc acc ggc agt acg tat gac atg ggc tgg 96 Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr Asp Met Gly Trp 20 30																				
30		ttc cgc cag gct cca ggg aag gag cgt gag tct gta gca gct att aac 144 Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val Ala Ala Ile Asn 35 40 45																				
35		tgg gat agt gcg cgc aca tac tat gca agc tcc gtg agg ggc cga ttc 192 Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val Arg Gly Arg Phe 50 55 60																				
40		acc atc tcc aga gac aac gcc aag aag acg gtg tat ctg caa atg aac 240 Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu Gln Met Asn 65 70 75 80																				
45		agc ctg aaa cct gag gac acg gcc gtt tat acc tgt ggc gcg ggg gaa 288 Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Gly Ala Gly Glu 85 90 95																				
50		ggt ggt act tgg gac tcc tgg ggc cag ggg acc cag gtc acc gtc tcc 336 Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser 100 105 110																				
55		tca cag gtg cag ctg cag gag tca ggg gga ggc ttg gtg cag gct ggg 384 Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly 115 120 125																				
60		gag tct ctg aaa ctc tcc tgt gca gcc tct gga aac acc ttc agt ggc 432 Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly 130 135 140																				
65		ggc ttc atg ggc tgg tac cgc cag gct cca ggg aag cag cgc gag ttg 480 Gly Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu 145 150 155 160																				
70		gtc gca acc att aat agt aga ggt atc aca aac tat gca gac ttc gtg 528 Val Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val 165 170 175																				
75		aag ggc cga ttc acc atc tcc aga gac aat gcc aag aag aca gtg tat 576 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr 180 185 190																				

	ttg	gaa	atg	aac	agc	ctg	gaa	cct	gaa	gac	acg	gcc	gtt	tat	tac	tgt	624
	Leu	Glu	Met	Asn	Ser	Leu	Glu	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
			195					200					205				
5	tac	act	cac	tac	ttc	aga	tcc	tac	tgg	ggg	cag	ggg	acc	cag	gtc	acc	672
	Tyr	Thr	His	Tyr	Phe	Arg	Ser	Tyr	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	
		210					215					220					
10	<210>	33															
	<211>	224															
	<212>	PRT															
	<213>	Artificial Sequence															
15	<223>	Description of Artificial Sequence: PLASMID CONSTRUCT															
	<400>	33															
	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Ala	Gly	Gly	Ser	Leu	Arg	Leu	
	1				5					10					15		
20	Ser	Cys	Ala	Ala	Ser	Gly	Arg	Thr	Gly	Ser	Thr	Tyr	Asp	Met	Gly	Trp	
			20						25					30			
25	Phe	Arg	Gln	Ala	Pro	Gly	Lys	Glu	Arg	Glu	Ser	Val	Ala	Ala	Ile	Asn	
			35					40					45				
	Trp	Asp	Ser	Ala	Arg	Thr	Tyr	Tyr	Ala	Ser	Ser	Val	Arg	Gly	Arg	Phe	
		50					55					60					
30	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Lys	Thr	Val	Tyr	Leu	Gln	Met	Asn	
	65					70					75					80	
	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Thr	Cys	Gly	Ala	Gly	Glu	
					85					90					95		
35	Gly	Gly	Thr	Trp	Asp	Ser	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	
				100					105					110			
40	Ser	Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Ala	Gly	
			115					120					125				
	Glu	Ser	Leu	Lys	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Asn	Thr	Phe	Ser	Gly	
		130					135					140					
45	Gly	Phe	Met	Gly	Trp	Tyr	Arg	Gln	Ala	Pro	Gly	Lys	Gln	Arg	Glu	Leu	
	145					150					155					160	
	Val	Ala	Thr	Ile	Asn	Ser	Arg	Gly	Ile	Thr	Asn	Tyr	Ala	Asp	Phe	Val	
					165					170					175		
50	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Lys	Thr	Val	Tyr	
				180					185					190			
55	Leu	Glu	Met	Asn	Ser	Leu	Glu	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
			195					200					205				
	Tyr	Thr	His	Tyr	Phe	Arg	Ser	Tyr	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	
		210					215					220					
60	<210>	34	</														

WO 00/24884

12

PCT/EP99/08323

<220>  
 <223> Description of Artificial Sequence:SYNTHETIC  
 INSERT

5 <400> 34 48  
 gtcaccgtct ctagatggcc accaggtgca gctgcaggag tcaactta

10 <210> 35  
 <211> 47  
 <212> DNA  
 <213> Artificial Sequence

15 <220>  
 <223> Description of Artificial Sequence:SYNTHETIC  
 INSERT

20 <400> 35 47  
 gcagagatct accggtggtc cacgtcgagc tcctcagttg aattcga

25 <210> 36  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> Description of Artificial Sequence:LINKER

35 <400> 36 23  
 ctagtggtac ttccggttcc cag

40 <210> 37  
 <211> 16  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <223> Description of Artificial Sequence:LINKER

50 <400> 37 16  
 accatgaagg ccaagg

55 <210> 38  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

60 <220>  
 <223> Description of Artificial Sequence:LINKER

65 <400> 38 35  
 ctagttcttc atctgcttct gcctcttcag ccag

60 <210> 39  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

65 <220>  
 <223> Description of Artificial Sequence:LINKER

WO 00/24884

13

PCT/EP99/08323

<400> 39  
aagaagtaga cgaagacgga gaagtcgg 28

5 <210> 40  
<211> 29  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence:LINKER

<400> 40  
ctagtgggtc tccaggttca ccaggtcag 29

15

<210> 41  
<211> 22  
<212> DNA  
20 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:LINKER

25 <400> 41  
accaagaggt ccaagtggc ca 22

30 <210> 42  
<211> 41  
<212> DNA  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence:LINKER

<400> 42  
ctagtgtac tacaactggt tcttcaccag gtccaactca g 41

40

<210> 43  
<211> 34  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence:LINKER

<400> 43  
50 acgatgatgt tgaccaagaa gtggtccagg ttga 34

55 <210> 44  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:LINKER

60 <400> 44  
ctagtgtcaa tcattctggt aatgcttctc ag 32

65 <210> 45

WO 00/24884

14

PCT/EP99/08323

<211> 25  
<212> DNA  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence:LINKER

<400> 45  
acgattagta agaccattac gaaga

25

10



PTO/PCT Rec'd 03 JUL 2002

SEQUENCE LISTING

<110> Unilever PLC  
Unilever N.V.  
FRENKEN, Leo G. J.  
HOWELL, Steven  
VAN DER VAART, Jan M.

<120> Antigen-Binding Proteins

<130> 56159-5041

<140> US 09/807,172

<141> 2001-04-10

<150> PCT/EP98/06991

<151> 1998-10-27

<150> EP 99303118.6

<151> 1999-04-22

<150> PCT/EP99/08323

<151> 1999-10-22

<160> 51

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> Linker sequence

<400> 1

Gly Thr Ser Gly Ser

1 5

<210> 2

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Linker sequence

<400> 2

Ser Ser Ser Ala Ser Ala Ser Ser Ala

1 5

<210> 3



<220>

<223> Primer

<400> 7

aacagttaag cttccgcttg cggccgcgga gctgggggtct tcgctgtggt gcg 53

<210> 8

<211> 53

<212> DNA

<213> Artificial sequence

<220>

<223> Primer

<400> 8

aacagttaag cttccgcttg cggccgcgtgg ttgtggtttt ggtgtcttgg gtt 53

<210> 9

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Primer

<400> 9

gggaattcca ataggtggtt agcaatcg 28

<210> 10

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> Primer

<400> 10

gaccaacgtg gtcgcctggc aaaacg 26

<210> 11

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> Primer

<400> 11

cgttttgccg ggcgaccacg ttggtc 26

<210> 12

<211> 30  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer

<400> 12  
 ccccaagctt acatgggtctt aagttggcgt 30

<210> 13  
 <211> 155  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Plasmid construct

<400> 13  
 gagctcatca cacaacaaaa caaaacaaaa tgatgctttt gcaagccttc cttttccttt 60  
 tggctggttt tgcagccaaa atatctgcgc aggtgcagct gcaggagtca taatgagggg 120  
 cccaggtcac cgtctcctca taatgactta agctt 155

<210> 14  
 <211> 36  
 <212> PRT  
 <213> Artificial sequence

<220>  
 <223> Plasmid construct

<400> 14  
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala Phe  
 1 5 10 15

Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val Gln  
 20 25 30

Leu Gln Glu Ser  
 35

<210> 15  
 <211> 8  
 <212> PRT  
 <213> Artificial sequence

<220>  
 <223> Plasmid construct







Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr Val  
100 105 110

Ser Ser

<210> 23  
<211> 351  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Plasmid Construct

<220>  
<221> CDS  
<222> (1)..(351)  
<223>

<400> 23  
cag gtg cag ctg cag gag tca ggg gga gga ttg gtg cag gcg ggg ggc 48  
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly  
1 5 10 15  
tct ctg aga ctc tcc tgt gca gcc tct gga cgc acc ggc agt acg tat 96  
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr  
20 25 30  
gac atg ggc tgg ttc cgc cag gct cca ggg aag gag cgt gag tct gta 144  
Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val  
35 40 45  
gca gct att aac tgg gat agt gcg cgc aca tac tat gca agc tcc gtg 192  
Ala Ala Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val  
50 55 60  
agg ggc cga ttc acc atc tcc aga gac aac gcc aag aag acg gtg tat 240  
Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr  
65 70 75 80  
ctg caa atg aac agc ctg aaa cct gag gac acg gcc gtt tat acc tgt 288  
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys  
85 90 95  
ggc gcg ggg gaa ggt ggt act tgg gac tcc tgg ggc cag ggg acc cag 336  
Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln  
100 105 110  
gtc acc gtc tcc tca 351  
Val Thr Val Ser Ser  
115



[illegible]

<400> 24

43

9

<223> Primer

ccctgggtcc agtggcagag gagtggcaga ggagtcttgt tt

42

<213> Artificial sequence

<223> Primer

caggtccagc tgcaggagtc tggg

24

<213> Artificial sequence

<223> Primer

caggtgaaac tgctcgagtc wggg

24

<213> Artificial sequence

<223> Linker; Double stranded

<223>

g gtc acc gtc tcc tca cag gtg cag ctg cag gag tca ctg taatgactta

50

Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Leu

1                      5                      10

agctt

55

&lt;212&gt; PRT

<213> Artificial sequence

<220>

<223> Linker; Double stranded

<400> 30

Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Leu  
1 5 10

<210> 31

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> Primer

<400> 31

Gln Val Gln Leu Gln Glu Ser Gly  
1 5

<210> 32

<211> 672

<212> DNA

<213> Artificial sequence

<220>

<223> Plasmid Construct

<220>

<221> CDS

<222> (1)..(672)

<223>

<400> 32

ctc gag tca ggg gga gga ttg gtg cag gcg ggg ggc tct ctg aga ctc 48  
Leu Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu  
1 5 10 15

tcc tgt gca gcc tct gga cgc acc ggc agt acg tat gac atg ggc tgg 96  
Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr Asp Met Gly Trp  
20 25 30

ttc cgc cag gct cca ggg aag gag cgt gag tct gta gca gct att aac 144  
Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val Ala Ala Ile Asn  
35 40 45

tgg gat agt gcg cgc aca tac tat gca agc tcc gtg agg ggc cga ttc 192  
Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val Arg Gly Arg Phe  
50 55 60

acc atc tcc aga gac aac gcc aag aag acg gtg tat ctg caa atg aac 240  
Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu Gln Met Asn

65	70	75	80	
agc ctg aaa cct gag gac acg gcc gtt tat acc tgt ggc gcg ggg gaa				288
Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Gly Ala Gly Glu	85	90	95	
ggt ggt act tgg gac tcc tgg ggc cag ggg acc cag gtc acc gtc tcc				336
Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser	100	105	110	
tca cag gtg cag ctg cag gag tca ggg gga ggc ttg gtg cag gct ggg				384
Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly	115	120	125	
gag tct ctg aaa ctc tcc tgt gca gcc tct gga aac acc ttc agt ggc				432
Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly	130	135	140	
ggc ttc atg ggc tgg tac cgc cag gct cca ggg aag cag cgc gag ttg				480
Gly Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu	145	150	155	160
gtc gca acc att aat agt aga ggt atc aca aac tat gca gac ttc gtg				528
Val Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val	165	170	175	
aag ggc cga ttc acc atc tcc aga gac aat gcc aag aag aca gtg tat				576
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr	180	185	190	
ttg gaa atg aac agc ctg gaa cct gaa gac acg gcc gtt tat tac tgt				624
Leu Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys	195	200	205	
tac act cac tac ttc aga tcc tac tgg ggt cag ggg acc cag gtc acc				672
Tyr Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr	210	215	220	

<210> 33  
 <211> 224  
 <212> PRT  
 <213> Artificial sequence

<220>  
 <223> Plasmid Construct

<400> 33

Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Ala	Gly	Gly	Ser	Leu	Arg	Leu
1				5					10					15	

Ser	Cys	Ala	Ala	Ser	Gly	Arg	Thr	Gly	Ser	Thr	Tyr	Asp	Met	Gly	Trp
		20						25					30		

Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val Ala Ala Ile Asn  
35 40 45

Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val Arg Gly Arg Phe  
50 55 60

Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu Gln Met Asn  
65 70 75 80

Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Gly Ala Gly Glu  
85 90 95

Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser  
100 105 110

Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly  
115 120 125

Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly  
130 135 140

Gly Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu  
145 150 155 160

Val Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val  
165 170 175

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr  
180 185 190

Leu Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys  
195 200 205

Tyr Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr  
210 215 220

<210>	34
<211>	48
<212>	DNA
<213>	Artificial sequence

<220>  
<223> Synthetic Insert

<400> 34

48

```
<210> 35
<211> 47
<212> DNA
<213> Artificial sequence
```

<220>  
<223> Synthetic insert

```
<400> 35
gcagagatct accggtggtc cacgtcgagc tcctcagttg aattcga
```

47

<210>	36
<211>	23
<212>	DNA
<213>	Artificial sequence

```
<220>
<223> Linker
```

<400> 36  
ctagtggtag ttccggttcc cag

23

```
<210> 37
<211> 16
<212> DNA
<213> Artificial sequence
```

```
<220>
<223> Linker
```

<400> 37  
accatgaagg ccaagg

16

```
<210> 38
<211> 35
<212> DNA
<213> Artificial sequence
```

<220>  
<223> Linker

<400> 38  
ctagttcttc atctgcttct gcctcttcag cccag

35

<210>	39
<211>	28
<212>	DNA
<213>	Artificial sequence

 $\langle 220 \rangle$

<223> Linker

<400> 39

aagaagtaga cgaagacgga gaagtcgg

28

<210> 40

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Linker

<400> 40

ctagtgggtc tccaggttca ccaggtcag

29

<210> 41

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Linker

<400> 41

accaagaggt ccaagtgggtc ca

22

<210> 42

<211> 41

<212> DNA

<213> Artificial sequence

<220>

<223> Linker

<400> 42

ctagtgtac tacaactggt tottcaccag gtccaactca g

41

<210> 43

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Linker

<400> 43

acgatgatgt tgaccaagaa gtgggtccagg ttga

34

<210> 44

<211> 32

<212> DNA

<213> Artificial sequence

<220>

<223> Linker

<400> 44

ctagtgctaa tcattctggt aatgcttctc ag

32

<210> 45

<211> 25

<212> DNA

<213> Artificial sequence

 $\langle 220 \rangle$ 

<223> Linker

<400> 45

acgattagta agaccattac gaaga

25

<210> 46

<211> 8

<212> PRT

<213> Artificial sequence

 $\langle 220 \rangle$ 

<223> Primer

<400> 46

Gln Val Lys Leu Leu Glu Ser Gly

1

(5)

<210> 47

<211> 7

<212> PRT

<213> Artificial sequence

 $\langle 220 \rangle$ 

<223> Linker Fragment

<400> 47

Ser Gly Thr Ser Gly Ser Gln

1

5

<210> 48

<211> 11

<212> PRT

<213> Artificial sequence

 $\langle 220 \rangle$ 

<223> Linker Fragment



<400> 48

Ser Ser Ser Ser Ala Ser Ala Ser Ser Ala Gln  
1 5 10

<210> 49

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Linker Fragment

<400> 49

Ser Gly Ser Pro Gly Ser Pro Gly Gln  
1 5

<210> 50

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> Linker Fragment

<400> 50

Ser Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro Thr Gln  
1 5 10

<210> 51

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> Linker Fragment

<400> 51

Ser Ala Asn His Ser Gly Asn Ala Ser Gln  
1 5 10